Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
This article was originally published in The Pink Sheet Daily
Executive Summary
Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.
You may also be interested in...
CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.
GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.